TUMOR, SOLID

This early-phase study tests a personalized mRNA vaccine (RGL-270) designed to train the immune system to recognize and attack leftover cancer cells after standard treatment. It is for adults aged 18-75 with solid tumors who have a high risk of recurrence. The vaccine is given al…

This early-stage study tests a drug called nab-sirolimus in people with advanced solid tumors who also have moderate liver impairment. The goal is to find a safe dose and see how the body processes the drug. About 28 adults will take part, and the study is currently recruiting.

This program provides an experimental drug called AVM0703 to people with various cancers, including brain tumors, breast cancer, and leukemia. It is available in the US when a doctor requests it. So far, 37 patients have received the treatment, and side effects have been mostly m…

This study tests whether a structured nutrition program can prevent malnutrition in children with solid tumors. About 400 children will receive either standard care or a team-based nutrition plan that includes special short-peptide supplements. The goal is to improve weight, heig…

This early-phase study tests a new drug called INV-1120, either by itself or combined with pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and check for side effects. About 7…

This study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to control or shrink advanced solid tumors like lung, pancreas, and colorectal cancers. The study involves 54 adults who…

This early-stage study tests two drugs, ulixertinib and palbociclib, together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find the safest dose and check for side effects. About 45 adults whose cancer has not respond…

This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for si…

This early-stage trial tests a new treatment called LEU011 for people with solid tumors that have not responded to standard therapies or have returned. LEU011 uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to check safe…

This early-phase study tests a personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations. The treatment uses a patient's own immune cells, engineered to recognize and attack cancer cells. The main goal is to check safety and find the right …

This early-phase study tests a new cell therapy (NW-301V or NW-301D) in 9 adults with advanced solid tumors that have specific KRAS mutations (G12V or G12D) and no standard treatment options. Participants receive their own immune cells that have been genetically engineered to rec…

This is the first study in people testing a new antibody drug called NTX-1088, which targets a protein found on many cancer cells. The trial will test the safety of NTX-1088 given alone and in combination with an existing immunotherapy drug (pembrolizumab) in 90 patients with adv…

This study tests a dye called indocyanine green that makes tumors glow under special cameras during surgery. The goal is to help surgeons find and remove all cancerous tissue, even tiny bits that are hard to see with the naked eye. About 500 adults with solid tumors will take par…

This study is for people with cancer who are about to start or have already received FDA-approved immunotherapy. Researchers want to see if special blood tests (immune-methylation and cytokine profiling) can predict whether the treatment will work. The goal is to better understan…